tetano
Editor, Senior Moderator
Clin Infect Dis
. 2022 Jul 29;ciac625.
doi: 10.1093/cid/ciac625. Online ahead of print.
Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality
Jennifer Kertes[SUP] 1 [/SUP], Shirley Shapiro Ben David[SUP] 2 3 [/SUP], Noya Engel-Zohar[SUP] 4 [/SUP], Keren Rosen[SUP] 1 3 [/SUP], Beatriz Hemo[SUP] 1 [/SUP], Avner Kantor[SUP] 1 [/SUP], Limor Adler[SUP] 1 3 [/SUP], Naama Shamir Stein[SUP] 1 [/SUP], Miri Mizrahi Reuveni[SUP] 2 [/SUP], Arnon Shahar[SUP] 5 [/SUP]
Affiliations
Abstract
Background: Intramuscular AZD7442 (Tixagevimab-Cilgavimab, (Evusheld)) has been found effective among immunocompromised individuals (ICI) in reducing Sars-Cov-2 infection and severe disease in ICIs. We evaluated the association between AZD7442 administration and SARS-CoV-2 infection and severe disease (COVID-19 hospitalization and all-cause mortality) among selected ICIs, during a fifth Omicron-dominated wave of COVID-19 (Dec 2021-April 2022) in Israel.
Methods: ICIs aged 12 and over identified in the Maccabi HealthCare Services database were invited by SMS/email to receive AZD7442. Demographic information, comorbidities, coronavirus vaccination and prior SARS-CoV-2 infection and COVID-19 outcome data (infection, severe disease), were extracted from the database. Rates of infection and severe disease were compared between those administered AZD7442 and those who did not respond to the invitation, over a three-month period.
Results: Of all 825 ICIs administered AZD7442, 29 (3.5%) became infected with SARS-CoV-2 compared to 308 (7.2%) of 4299 ICIs not administered AZD7442 (p < 0.001). After adjustment, the AZD7442 group were half as less likely to become infected with Sars-Cov-2 than the non-administered group (OR: 0.51, 95% CI: 0.30-0.84). One person in the AZD7442 group (0.1%) was hospitalized for COVID-19 compared to 27 (0.6%) in the non-administered group (p = 0.07). No mortality was recorded among the AZD7442 group, compared to 40 deaths (0.9%) in the non-administered group (p = 0.005). After adjustment, ICIs administered AZD7442 were 92% less likely to be hospitalized/die than those not administered AZD7442 (OR: 0.08, 95% CI: 0.01-0.54).
Conclusions: AZD7442 among ICI may protect against Omicron variant infection and severe disease, and should be considered for pre-exposure prophylactic AZD7442.
Keywords: COVID-19; Evusheld; Omicron; immunocompromised; tixagevimab-Cilgavimab.
. 2022 Jul 29;ciac625.
doi: 10.1093/cid/ciac625. Online ahead of print.
Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality
Jennifer Kertes[SUP] 1 [/SUP], Shirley Shapiro Ben David[SUP] 2 3 [/SUP], Noya Engel-Zohar[SUP] 4 [/SUP], Keren Rosen[SUP] 1 3 [/SUP], Beatriz Hemo[SUP] 1 [/SUP], Avner Kantor[SUP] 1 [/SUP], Limor Adler[SUP] 1 3 [/SUP], Naama Shamir Stein[SUP] 1 [/SUP], Miri Mizrahi Reuveni[SUP] 2 [/SUP], Arnon Shahar[SUP] 5 [/SUP]
Affiliations
- PMID: 35904210
- DOI: 10.1093/cid/ciac625
Abstract
Background: Intramuscular AZD7442 (Tixagevimab-Cilgavimab, (Evusheld)) has been found effective among immunocompromised individuals (ICI) in reducing Sars-Cov-2 infection and severe disease in ICIs. We evaluated the association between AZD7442 administration and SARS-CoV-2 infection and severe disease (COVID-19 hospitalization and all-cause mortality) among selected ICIs, during a fifth Omicron-dominated wave of COVID-19 (Dec 2021-April 2022) in Israel.
Methods: ICIs aged 12 and over identified in the Maccabi HealthCare Services database were invited by SMS/email to receive AZD7442. Demographic information, comorbidities, coronavirus vaccination and prior SARS-CoV-2 infection and COVID-19 outcome data (infection, severe disease), were extracted from the database. Rates of infection and severe disease were compared between those administered AZD7442 and those who did not respond to the invitation, over a three-month period.
Results: Of all 825 ICIs administered AZD7442, 29 (3.5%) became infected with SARS-CoV-2 compared to 308 (7.2%) of 4299 ICIs not administered AZD7442 (p < 0.001). After adjustment, the AZD7442 group were half as less likely to become infected with Sars-Cov-2 than the non-administered group (OR: 0.51, 95% CI: 0.30-0.84). One person in the AZD7442 group (0.1%) was hospitalized for COVID-19 compared to 27 (0.6%) in the non-administered group (p = 0.07). No mortality was recorded among the AZD7442 group, compared to 40 deaths (0.9%) in the non-administered group (p = 0.005). After adjustment, ICIs administered AZD7442 were 92% less likely to be hospitalized/die than those not administered AZD7442 (OR: 0.08, 95% CI: 0.01-0.54).
Conclusions: AZD7442 among ICI may protect against Omicron variant infection and severe disease, and should be considered for pre-exposure prophylactic AZD7442.
Keywords: COVID-19; Evusheld; Omicron; immunocompromised; tixagevimab-Cilgavimab.